Under construction – not a live service

Skip to content

Frontlight Research

Institution

Goethe University Frankfurt

Frankfurt am Main, GermanyWebsite

Also known as: Goethe-Universität Frankfurt am Main · Johann Wolfgang Goethe-Universität Frankfurt am Main

218running trials
88closed trials
152,507publications (OpenAlex)

Running trials

Not yet recruiting
A trial to learn how safe newer immunotherapy drugs are and how well they work with or without other anti-cancer drugs in adults with advanced, unresectable non-small cell lung cancer
2025-523599-21-00· Phase 2· AstraZeneca AB· Source
Not yet recruiting
PD-1 Blockade Alone Versus in Combination With Chemotherapy as First Line Therapy in Females With Advanced NSCLC & PD-L1 Expression ≥50%
NCT07877584· Phase 3· German Cancer Research Center· Source
Not yet recruiting
Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets
NCT07234877· Phase 2· European Organisation for Research and Treatment of Cancer - EORTC· Source
Not yet recruiting
A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis
NCT07873801· Phase 3· Almirall, S.A.· Source
Not yet recruiting
Study of the safety and efficacy of asciminib in pediatric and young adult participants with r/r Ph+ or ABL-class Ph-like ALL
2025-522019-40-00· Phase 1/2· Novartis Pharma AG· Source
Recruiting
A clinical trial to learn about the effects of IEV407 when given alone or with endocrine therapy in people with advanced breast cancer
2025-522707-26-00· Phase 1· Novartis Pharma AG· Source
Not yet recruiting
A study to Evaluate the Efficacy and Safety of ENV-294 in Adult Participants with Moderate-to-Severe Atopic Dermatitis
2026-526184-38-00· Phase 2· Enveda Therapeutics Inc.· Source
Recruiting
Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
NCT07711002· Phase 3· AstraZeneca· Source
Recruiting
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT07680764· Phase 2· Bristol-Myers Squibb· Source
Not yet recruiting
A Randomized, Double-Blind, Placebo-controlled, Parallel Arm, 52-week Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of Two Doses of EXPD-101 in Participants with COPD
2026-525216-34-00· Phase 2· Expedition Therapeutics Inc.· Source
Not yet recruiting
A Trial for the Treatment of Advanced Large-Cell Neuroendocrine Cancer of the Lung
NCT07561645· Phase 2· Technische Universität Dresden· Source
Not yet recruiting
AIEOP-BFM ALL 2025 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia
2025-522190-11-01· Phase 3· Universitaetsklinikum Schleswig-Holstein AöR· Source
Recruiting
Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer
NCT07564141· Phase 3· Genmab· Source
Recruiting
Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy
2025-524335-39-00· Phase 3· Gilead Sciences Inc.· Source
Recruiting
Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome
NCT07247162· Phase 4· RECORDATI GROUP· Source
Recruiting
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
NCT07784725· Phase 3· AstraZeneca· Source
Recruiting
The RAPID-Elapse study: Can the drug bupropion improve fatigue symptoms in patients with long COVID?
2025-524443-12-00· Phase 2· Goethe University Frankfurt· Source
Recruiting
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS
NCT07665437· Phase 3· Novartis Pharmaceuticals· Source
Not yet recruiting
Does a higher radiation dose prolong survival of patients with limited-stage small cell lung cancer receiving immunotherapy after chemotherapy and radiation therapy (DAHRTS trial)?
2026-525513-31-00· Phase 3· Norges Teknisk-Naturvitenskapelige Universitet NTNU· Source
Not yet recruiting
GMMG-HD11/DSMM XXI/64007957MMY3010
NCT07671287· Phase 3· University of Heidelberg Medical Center· Source
Recruiting
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
NCT07555938· Phase 3· Hoffmann-La Roche· Source
Recruiting
Dehydroepiandrosterone (DHEA) as Augmentation of Standard Antidepressants in Treatment-resistant Depression.
NCT07843927· Phase 3· Charite University, Berlin, Germany· Source
Recruiting
Study to evaluate the safety and efficacy of asciminib in pediatric participants with chronic myeloid leukemia.
2025-522138-29-00· Phase 2· Novartis Pharma AG· Source
Recruiting
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer (HARMONi-GI3)
2025-521587-35-00· Phase 3· Summit Therapeutics Inc.· Source
Recruiting
PREFer
NCT06916416· Phase 2· University Of Cologne· Source
Not yet recruiting
A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APPROACH. ALL-TARGET TRIAL
2024-516570-30-00· Phase 2· Centre Hospitalier De Versailles· Source
Recruiting
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
NCT07525206· Phase 3· AbbVie· Source
Recruiting
A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A
NCT07416526· Phase 3· Hoffmann-La Roche· Source
Recruiting
Pembro-FLASH
NCT06045159· Phase 2· University Of Cologne· Source
Recruiting
A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
NCT07416604· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa
2025-522440-41-00· Phase 2· Bluefin Biomedicine Inc.· Source
Recruiting
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
NCT07342478· Phase 3· Newave Pharmaceutical Inc· Source
Recruiting
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
NCT07226843· Phase 1· Eli Lilly and Company· Source
Recruiting
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
NCT07472517· Phase 3· Boehringer Ingelheim· Source
Recruiting
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
NCT07291076· Phase 1/2· Bristol-Myers Squibb· Source
Recruiting
A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
NCT07491497· Phase 1/2· TRIANA Biomedicines, Inc.· Source
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
NCT07282574· Phase 2· Hoffmann-La Roche· Source
Recruiting
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
NCT07431177· Phase 2· Novartis Pharmaceuticals· Source
Recruiting
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
NCT07223814· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source
Recruiting
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
NCT07449702· Phase 2· Oruka Therapeutics, Inc.· Source
Recruiting
Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD
NCT07441395· Phase 2· Corvus Pharmaceuticals, Inc.· Source
Recruiting
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
NCT07155226· Phase 1/2· AstraZeneca· Source
Recruiting
A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa
NCT07384975· Phase 2· Navigator Medicines, Inc.· Source
Active, not recruiting
A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis
NCT07277660· Phase 2· UCB Biopharma SRL· Source
Recruiting
Registry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residual disease.
2024-512503-39-00· Phase 4· Medizinische Hochschule Hannover· Source
Recruiting
STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease
NCT07280585· Phase 3· University of Cologne· Source
Recruiting
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
NCT06793397· Phase 3· Cybin IRL Limited· Source
Recruiting
SGLT2 Inhibition for Cardiovascular Endpoint Reduction in Hypertension
NCT06804161· Phase 3· Prof. Dr. med. Ingo Eitel· Source
Recruiting
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
NCT07221253· Phase 3· AstraZeneca· Source
Recruiting
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
NCT07250802· Phase 3· Takeda· Source

Showing 50 of 218.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Closed trials

Completed
A multi-part, adaptive, Phase 1, first time in human study in healthy participants and participants with atopic dermatitis (AD) to assess the safety, tolerability, pharmacokinetics (PK) of single ascending (SAD), multiple ascending doses (MAD) and selected dose of SYX-5219 (AD Participants)
2025-522216-17-00· Phase 1· Sitryx Therapeutics Limited· Source
Completed
Study of the Effectiveness and Safety of Acasunlimab Alone or With Pembrolizumab in treating Advanced Melanoma of the Skin That Has Returned After or did not respond to Cancer Immunotherapy (ABBIL1TY MELANOMA-07)
NCT06984328· Phase 2· Genmab A/S· Source
Active, not recruiting
Study of zoldonrasib in Previously Treated Patients with RAS G12D-Mutant Non-Small Cell Lung Cancer (NSCLC)
2025-521681-10-00· Phase 2· Revolution Medicines Inc.· Source
Completed
Phase 2b Randomized, Double-Blind Study with Phage for CF Subjects with Pseudomonas Lung Infection
2024-519856-94-00· Phase 2· Biomx Ltd.· Source
Completed
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease
NCT06926660· Phase 2· Boehringer Ingelheim· Source
Completed
A study to investigate efficacy and safety of SAR441566 in patients with ulcerative colitis
NCT06867094· Phase 2· Sanofi-Aventis Recherche & Developpement· Source
Completed
A Phase 2 Study of PRT3789 in Combination with Pembrolizumab in Patients with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation
NCT06682806· Phase 2· Prelude Therapeutics Inc.· Source
Completed
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis
2024-517814-13-00· Phase 2· Janssen Cilag International· Source
Completed
Surgical or radiotherapeutic intervention concerning large singular stable to progressive metastases in patients with BRAFV600-mutated melanoma receiving treatment with Encorafenib + Binimetinib
2024-516073-74-00· Phase 4· SRH Wald-Klinikum Gera GmbH· Source
Active, not recruiting
Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)
NCT06726265· Phase 3· Immutep S.A.S.· Source
Completed
A Study of ZW171 in Participants with Advanced or Metastatic Mesothelin Expressing Cancers
2024-511119-11-00· Phase 1· Zymeworks Inc.· Source
Completed
Phase 2, randomized, double-blind, placebo-controlled study of IC0624 as first-line therapy in patients with active mild to moderate Hidradenitis Suppurativa (HS)
2024-518180-35-00· Phase 2· Ichthyol-Gesellschaft Cordes Hermanni & Co. GmbH & Co. KG· Source
Active, not recruiting
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
NCT06744920· Phase 3· Novartis Pharmaceuticals· Source
Terminated
Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa
NCT06555328· Phase 2· InflaRx GmbH· Source
Completed
A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia
2024-511057-22-00· Phase 3· Janssen Cilag International· Source
Completed
Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures – SHINE
NCT06425159· Phase 2/3· Biohaven Therapeutics Ltd.· Source
Completed
A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis
NCT06602219· Phase 2· DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company· Source
Completed
A trial to learn if AZD9829 is safe and works alone and in combination with other treatments for participants with certain blood cancers.
NCT06179511· Phase 1· Astrazeneca AB· Source
Recruiting
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
NCT06585787· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source
Completed
A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa
NCT06603077· Phase 2· Avalo Therapeutics, Inc.· Source
Completed
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis
NCT06586112· Phase 3· Alumis Inc· Source
Completed
Randomized adaptive assessment of post COVID syndrome treatments (RAPID) Reducing Inflammatory Activity in Patients with post COVID Syndrome (REVIVE)
2024-511628-16-00· Phase 2· Goethe University Frankfurt· Source
Completed
A Study to Investigate LDL-cholesterol Lowering With Inclisiran Compared to Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease.
NCT06431763· Phase 4· Novartis Pharmaceuticals· Source
Active, not recruiting
Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma
NCT06216158· Phase 3· University of Heidelberg Medical Center· Source
Completed
Study of IMG-007 in Participants with Moderate to Severe Atopic Dermatitis
NCT05984784· Phase 1/2· Inmagene LLC· Source
Completed
An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants With Schizophrenia
NCT06315283· Phase 1· Teva Branded Pharmaceutical Products R&D LLC· Source
Completed
A proof of concept and dose-finding study of XXB750 in patients with heart failure
2023-504678-39-00· Phase 2· Novartis Pharma AG· Source
Active, not recruiting
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)
NCT06113445· Phase 3· Incyte Corporation· Source
Completed
A Study Evaluating the Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients with Surgically Resectable Hepatocellular Carcinoma (Morpheus-Neo HCC)
2022-502840-11-00· Phase 1/2· F. Hoffmann-La Roche AG· Source
Completed
A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06046729· Phase 2· Eli Lilly and Company· Source
Completed
A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated Flares
NCT06013969· Phase 4· LEO Pharma· Source
Completed
Magrolimab plus intensive chemotherapy in newly diagnosed “ELN intermediate or poor-risk” AML patients intended to undergo allogeneic stem cell transplantation, a Phase 2, Single-arm, Open-Label Study (MAGROLIC)
2022-502040-13-00· Phase 2· University of Leipzig· Source
Completed
A Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults with Tuberous Sclerosis Complex (TSC)-related Epilepsy (TrustTSC OLE)
NCT05604170· Phase 3· Marinus Pharmaceuticals Inc.· Source
Completed
A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis
NCT05923099· Phase 2· LEO Pharma· Source
Completed
Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia
2022-502233-25-00· Phase 3· Neurocrine Biosciences Inc.· Source
Completed
A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy
NCT05958407· Phase 3· LEO Pharma· Source
Completed
A multicentre, randomised, double-blind, placebo-controlled, 12-week parallel-group trial to evaluate the efficacy and safety of oral BP1.7881 in adult patients with moderate-to-severe atopic dermatitis
2022-502045-10-00· Phase 2· Bioprojet Pharma· Source
Completed
A Study Evaluating Pharmacokinetic Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Stage III and Stage IV Melanoma in the Adjuvant Setting
2022-502620-49-00· Phase 1· Amgen Inc.· Source
Recruiting
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
NCT05980949· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source
Completed
Long-term Safety and Efficacy of Efavaleukin Alfa in Subjects With Moderately to Severely Active Ulcerative Colitis
NCT05672199· Phase 2· Amgen Inc.· Source
Terminated
Hidradenitis Suppurativa Study of Izokibep
NCT05905783· Phase 3· ACELYRIN Inc.· Source
Completed
A 24-month study evaluating physical activity and joint health in patients 12 years and older, with severe haemophilia A treated once weekly with efanesoctocog alfa.
2022-500275-31-00· Phase 3· Swedish Orphan Biovitrum AB (publ)· Source
Completed
A Study to Test the Efficacy and Safety of SAR442970 in Adults With Hidradenitis Suppurativa
NCT05849922· Phase 2· Sanofi· Source
Completed
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease
NCT05771428· Phase 2· AbbVie· Source
Completed
A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV
NCT05904470· Phase 2· Atea Pharmaceuticals, Inc.· Source
Completed
A Trial of GH001 in Patients With Treatment-resistant Depression
NCT05800860· Phase 2· GH Research Ireland Limited· Source
Completed
Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participant With Moderate-to-Severe Atopic Dermatitis
NCT05916365· Phase 3· Almirall, S.A.· Source
Completed
A study to see how well CVGBM vaccine works at different doses and how safe it is in patients who had surgery for glioblastoma or astrocytoma
2022-501423-25-00· Phase 1/2· Curevac AG· Source
Active, not recruiting
An early access study of ivosidenib in patients with a pretreated locally advanced or metastatic cholangiocarcinoma
2022-501463-40-01· Phase 3· Servier Affaires Medicales· Source
Completed
A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2
NCT05737940· Phase 2· AstraZeneca· Source

Showing 50 of 88.

Registry name variants (5)

Trial registries list this institution under these names. Each row is one registry entry: its address and the trials registered under it.

Goethe University Frankfurt
Frankfurt Am Main, 60528
305 trials
Goethe University Frankfurt
Frankfurt
2 trials
- NCT06856837- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases
  Contact: Christine Koch, PD Dr.
- NCT05177835Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis
Department of Radiotherapy and Oncology, Goethe-University Frankfurt am Main
Frankfurt
1 trial
- NCT05337631Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy
  Contact: Alexander Rühle, MD, MHBA
Goethe Universität Frankfurt
Frankfurt am Main, 60590
1 trial
- NCT03573310A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS
Goethe-Universität Frankfurt am Main
Frankfurt am Main, Germany 60590

Conditions

Diseases this institution publishes on or runs trials for.

Institution data: ROR 04cvxnb49 (CC0-1.0)Updated 12 Nov 2026

Report an error

Under construction, not live – Goethe University Frankfurt: trials and research groups – Frontlight Research